How CBD Is Finally Paying Off for Amyris

Amyris shares jumped early on Monday on news that the firm had received its first payment from its cannabinoid partner.

Published May 20, 2019, 9:10am ET · 1 min read

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

© Dmitry_Tishchenko / Getty Images

Amyris Inc. (NASDAQ: AMRS) shares jumped early on Monday on news that the firm had received its first payment from its cannabinoid partner. Specifically, Amyris received $10 million from Lavvan for having successfully delivered on its first major collaboration milestone announced back in March.

With this successful collaboration with Lavvan to commercialize cannabinoid ingredients, Amyris is seeking to prove its ability to disrupt large markets, as well as its cost efficiently and sustainably.

The company expects to bring the first fermentation-derived cannabinoid products to market next year with better purity and at a significantly reduced cost compared to similar products and ingredients.

John Melo, president and CEO of Amyris, commented:

We are very pleased with the continued strong execution of our business strategy and the performance of our technology platform. We are also encouraged by the progress we’ve made thus far working with our valued partner, Lavvan, and our collaborative relationship with them on this project, which will be another cornerstone of our growth. Our brands and supply business are having a great year and our technology pipeline is delivering on our partners’ expectations.

Shares of Amyris closed Friday at $4.24, in a 52-week range of $1.87 to $9.29. The consensus price target is $11.00. Following the announcement, the stock was up about 8.5% at $4.60 in early trading indications Monday.


Contact [email protected] for any questions or corrections.

Chris Lange

Chris Lange is a financial and geopolitical writer with more than a decade of experience covering a myriad of topics. He has published thousands of articles for 24/7 Wall St., with past coverage focused heavily on stocks, IPOs, healthcare, defense, global affairs, and technology.

His work has been quoted, or referenced by a number of outlets including Business Insider, USA Today, Yahoo Finance, MSN, The Motley Fool, and many other publications. A graduate of Southwestern University, he studied business with a focus on investments and has previous experience in banking and startups.

When not reading or writing the news, he is following his passion for Lacrosse, playing chess, or building solar projects with his dad.

All articles →